Anthropic’s New AI Model Could Supercharge CrowdStrike’s Growth
Wolfe Research upgrades CrowdStrike to Outperform and sets a $450 price target.
Already have an account? Sign in.
Wolfe Research upgrades CrowdStrike to Outperform and sets a $450 price target.
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.
Genuine Parts lowered its 2026 profit outlook amid weaker consumer demand. CEO Will Stengel denied rumors of a rival acquiring its automotive business.